var data={"title":"Methoxsalen (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methoxsalen (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389806?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methoxsalen-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methoxsalen (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770717\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: Only health care providers who have special competence in the diagnosis and treatment of psoriasis and vitiligo (8-MOP only) and who have special training and experience in photochemotherapy should use methoxsalen with ultraviolet (UV) radiation. The use of psoralen and UV radiation therapy should be under constant supervision of such a health care provider. For the treatment of patients with psoriasis, restrict photochemotherapy to patients with severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, and only when the diagnosis is certain. Because of the possibility of ocular damage, skin aging, and skin cancer (including melanoma), fully inform the patient of the risks inherent in this therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Injection (photophoresis): Only health care providers who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and have special training and experience in the UVAR XTS or CELLEX photopheresis system should use methoxsalen. Consult the appropriate operator's manual before using this product.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Product interchange (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use Oxsoralen-Ultra (methoxsalen soft gelatin capsules) interchangeably with 8-MOP (methoxsalen hard gelatin capsules). Oxsoralen-Ultra soft gelatin capsules exhibit significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Treat patients in accordance with the dosimetry specifically recommended for this product. Determine the minimum phototoxic dose and phototoxic peak time after drug administration prior to the onset of photochemotherapy with this dosage form.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">8-MOP capsules may not be interchanged with Oxsoralen-Ultra capsules without retitration of the patient.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770721\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>8-Mop [DSC];</li>\n      <li>Oxsoralen Ultra;</li>\n      <li>Uvadex [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770722\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Uvadex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770782\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Psoralen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770883\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Refer to treatment protocols for UVA exposure guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 10 to 70 mg 1.5 to 2 hours (Oxsoralen Ultra) or 2 hours (8-MOP) before exposure to UVA light; dose may be repeated 2-3 times per week, based on UVA exposure; doses must be given at least 48 hours apart; dosage is based upon patient's body weight and skin type:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;30 kg: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 to 50 kg: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">51 to 65 kg: 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">66 to 80 kg: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">81 to 90 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">91 to 115 kg: 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;115 kg: 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosage may be increased (one time) by 10 mg after 15th treatment if minimal or no response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: When 95% psoriasis clearing achieved, may begin 1 treatment every week for at least 2 treatments; followed by 1 treatment every 2 weeks for at least 2 treatments; then every 3 weeks for at least 2 treatments then as needed to maintain response while minimizing UVA exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitiligo:</b> Oral (8-MOP): 20 mg 2 to 4 hours before exposure to UVA light; dose may be repeated based on erythema and tenderness of skin; do not give on 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous T-cell lymphoma (CTCL): </b> Extracorporeal (Uvadex): Dose is determined by treatment volume; amount of Uvadex needed for each treatment may be calculated using the following equation: Treatment volume x 0.017 = mL of Uvadex needed. Inject this amount into the recirculation bag prior to the photoactivation phase using the UVAR XTS or CELLEX photopheresis system (consult user's guide).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment schedule:</i> Two consecutive days every 4 weeks for a minimum of 7 treatment cycles (6 months), may accelerate to 2 consecutive days every 2 weeks if skin score worsens (eg, increases from baseline) after assessment during the fourth treatment cycle (~3 months). If skin score improves by 25% after 4 consecutive weeks of accelerated therapy, may resume regular treatment schedule. Patients maintained on accelerated therapy may receive a maximum of 20 accelerated therapy cycles. There is no clinical evidence to show that treatment with methoxsalen for more than 6 months or using a different schedule provides additional benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770884\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570404\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570405\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770913\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8-Mop: 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxsoralen Ultra: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow), methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Uvadex: 20 mcg/mL (10 mL [DSC]) [contains alcohol, usp, propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770764\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9531474\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: To reduce nausea, capsules should be administered with food or milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Extracorporeal: Do not inject solution directly into patients. Vial contents should be injected into the photoactivation bag of the UVAR XTS or CELLEX Photopheresis System immediately after being drawn up into a syringe. Solution can adsorb onto PVC and plastics; only UVAR XTS or CELLEX photopheresis procedural kits supplied for use with the instrument should be used to administer the product. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770810\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Symptomatic control of severe, recalcitrant disabling psoriasis; repigmentation of idiopathic vitiligo; palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extracorporeal: Palliative treatment of skin manifestations of CTCL that is unresponsive to other forms of treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770719\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Methoxsalen soft gelatin capsules (Oxsoralen-Ultra) may be confused with methoxsalen hard  gelatin capsules (8-MOP); bioavailability and photosensitization onset differ between the two products.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770818\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10%)</p>\n    <p style=\"text-indent:0em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypotension (due to photopheresis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, headache, insomnia, malaise, nervousness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bulla, burning sensation of skin, dermatological disease (premature aging), ephelis, erythema, exfoliation of skin, folliculitis, hypopigmentation, miliaria, skin blister (painful), skin neoplasm, skin rash, skin tenderness, skin vesicle, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (due to vascular access for photopheresis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770815\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to methoxsalen (psoralens) or any component of the formulation; diseases associated with photosensitivity (eg, albinism, lupus erythematosus, porphyria [cutanea tarda, erythropoietic and variegate], xeroderma pigmentosum); invasive squamous cell cancer (8-MOP and Oxsoralen Ultra only); aphakia; melanoma or history of melanoma (8-MOP and Oxsoralen Ultra only); contraindications to the photopheresis procedure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling (Uvadex):</i> Additional contraindications (not in US labeling): Severe cardiac disease; severe anemia; WBC &gt;25,000/mm<sup>3</sup>; previous splenectomy and coagulation disorders; basal cell cancer; coexisting melanoma; squamous cell carcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770816\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Actinic degeneration: Exposure to sunlight and/or ultraviolet radiation may result in premature aging of the skin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Burns: Serious burns may occur from ultraviolet radiation or sunlight (even if exposed through glass) if recommended dose and/or exposure schedule is not maintained. Avoid direct and indirect sunlight for 24 hours after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataracts: Methoxsalen concentrates in the lens; eyes should be shielded from direct and indirect sunlight for 24 hours after methoxsalen exposure to prevent possible formation of cataracts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid sun (including sun lamp) exposure for 24 hours after methoxsalen ingestion or administration. Protective clothing, eyewear, and sunscreen (do not apply sunscreen to psoriatic areas) should be used for 24 hours after combined methoxsalen/UVA therapy. Do not use in sunburned patients until they have fully recovered; pre-existing sunburn may obscure evaluation of response; advise patients to avoid sunbathing for 24 hours prior to treatment and for 48 hours after treatment. Use extreme caution in patients who have significant exposure to the sun through their occupation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin cancer: Therapy may lead to increased risk of skin cancer (basal cell, melanoma and squamous cell); this risk may be increased with fair skin or prior exposure to prolonged tar and UVB treatment, ionizing radiation, or arsenic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Have been reported, including pulmonary embolism and deep vein thrombosis in patients with graft-versus-host disease (methoxsalen is not FDA-approved for treatment of graft-versus-host disease).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Basal cell carcinoma: Use with caution in patients with multiple basal cell carcinomas or a history of basal cell carcinoma; observe closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (may not be able to tolerate the heat stress or prolonged standing related to UVA treatment conditions).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Methoxsalen undergoes hepatic metabolism; use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Use caution with other (systemic or topical) photosensitizing drugs (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides, nalidixic acid, halogenated salicylanilides, anthralin, coal tar preparations).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Safety and efficacy have not been established in children for cutaneous T-cell lymphoma (CTCL) or psoriasis and &lt;12 years of age for vitiligo. The long-term effects of treatment (including potential cataract formation, skin cancer development, and premature skin aging) are unknown in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: <b>[US Boxed Warning]: Soft-gelatin capsule (Oxsoralen-Ultra) and hard-gelatin capsule (8-MOP) are not interchangeable; retitration is required if the formulation is changed.</b> Oxsoralen-Ultra has a greater bioavailability and shorter onset of photosensitization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: CTCL: For use only if inadequate response to other forms of therapy. Used in conjunction with long wave radiation of white blood cells using the UVAR XTS or CELLEX photopheresis system.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Psoriasis: For use only if inadequate response to other therapies when the diagnosis is biopsy proven. Administer only in conjunction with scheduled controlled doses of long wave ultraviolet (UVA) radiation (combination referred to as PUVA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Vitiligo: Used in conjunction with controlled doses of long wave ultraviolet radiation or sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced physician with special competence in the diagnosis and treatment of dermatologic diseases.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770822\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate), CYP2A6 (strong), CYP2C9 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770823\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9577&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Use any such combination with caution and close monitoring for pirfenidone toxicity. Avoid the use of pirfenidone with moderate CYP1A2 inhibitors whenever CYP2C9, 2C19, 2C6, or 2E1 is also inhibited (either by the CYP1A2 inhibitor or by a third drug).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770847\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Methoxsalen serum concentrations may be increased if taken with food. Nausea can occur upon administration. Management: Capsules should be taken with food or milk. Avoid furocoumarin-containing foods (limes, figs, parsley, celery, cloves, lemon, mustard, carrots).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770811\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C/D (Uvadex) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770812\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Fetal toxicity has been observed in animal studies. Use during pregnancy is not recommended. Women of childbearing potential should be advised to avoid pregnancy. The Canadian labeling also recommends that male patients use effective contraception during and after photopheresis therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616217\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if methoxsalen (systemic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering methoxsalen (systemic) to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770885\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">To reduce nausea, capsules should be taken with food or milk. Avoid furocoumarin-containing foods (limes, figs, parsley, celery, cloves, lemon, mustard, carrots).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770902\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline and every 6-12 months), liver and renal function tests (baseline and every 6-12 months), antinuclear antibodies (baseline and every 6-12 months); ophthalmic exam (pretreatment and yearly); signs/symptoms of skin cancer, burns, and photosensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770848\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bonds covalently to pyrimidine bases in DNA, inhibits the synthesis of DNA, and suppresses cell division and epidermal turnover. The augmented sunburn reaction involves excitation of the methoxsalen molecule by radiation in the long-wave ultraviolet light (UVA), resulting in transference of energy to the methoxsalen molecule producing an excited state (&ldquo;triplet electronic state&rdquo;). The molecule, in this &ldquo;triplet state,&rdquo; then reacts with cutaneous DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770873\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Reversibly bound to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; forms metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Bioavailability increased with soft-gelatin capsules (Oxsoralen-Ultra) compared to hard-gelatin capsules (8-MOP); exposure using Uvadex with the UVAR photopheresis system is ~200 times less than with oral methoxsalen administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hard-gelatin capsules (8-MOP): 1.5 to 6 hours (peak photosensitivity: ~4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Soft-gelatin capsules (Oxsoralen Ultra): 0.5 to 4 hours (peak photosensitivity: 1.5 to 2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~95% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770915\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Methoxsalen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (50): $4,172.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Methoxsalen Rapid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (50): $4,005.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Oxsoralen Ultra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (50): $5,095.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961986\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Delsoralen (ID);</li>\n      <li>Lukodermine (PK);</li>\n      <li>Meladerm (LK);</li>\n      <li>Meladinina (CR, DO, GT, NI, PA, PY, SV);</li>\n      <li>Meladinine (CN, FR, TH, VN);</li>\n      <li>Melanocyl (IN);</li>\n      <li>Metoxaleno (UY);</li>\n      <li>Mopsalem (CO);</li>\n      <li>Mopsoralen (BE);</li>\n      <li>Neomeladinine (AE);</li>\n      <li>Oxsoralen (AE, AR, BB, BR, CL, CZ, HK, JO, JP, KW, LB, PL, QA, SA);</li>\n      <li>Oxsoralen Ultra (AE, BB, BH);</li>\n      <li>Sorialen (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    8-MOP (methoxsalen) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals; December 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxsoralen-Ultra (methoxsalen) [prescribing information insert]. Aliso Viejo, CA: Valeant Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stern RS, &ldquo;Psoralen and Ultraviolet a Light Therapy for Psoriasis,&rdquo; <i>N Engl J Med</i>, 2007, 357(7):682-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methoxsalen-systemic-drug-information/abstract-text/17699818/pubmed\" target=\"_blank\" id=\"17699818\">17699818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stern RS, Nichols KT and Vateva LH, &ldquo;Malignant Melanoma in Patients Treated for Psoriasis With Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA). The PUVA Follow-Up Study,&rdquo; <i>N Engl J Med</i>, 1997, 336(15):1041-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methoxsalen-systemic-drug-information/abstract-text/9091799/pubmed\" target=\"_blank\" id=\"9091799\">9091799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uvadex (methoxsalen) [prescribing information]. Greenville, NC: DSM Pharmaceuticals; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uvadex (methoxsalen) [Canadian product monograph]. West Chester, PA: Therakos Inc; May 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9577 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8770717\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8770721\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8770722\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8770782\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8770883\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8770884\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16570404\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570405\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8770913\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8770764\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9531474\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8770810\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8770719\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8770818\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8770815\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8770816\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8770822\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8770823\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8770847\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8770811\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8770812\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616217\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8770885\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8770902\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8770848\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8770873\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8770915\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961986\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9577|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methoxsalen-systemic-patient-drug-information\" class=\"drug drug_patient\">Methoxsalen (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}